Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease

Published on 01 Oct 2018
Last Updated on 01 Oct 2018

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Sevelamer carbonate 800 mg tablet for the treatment of hyperphosphataemia in patients with chronic kidney disease who:

  • have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders; or

  • cannot tolerate calcium-based phosphate binders due to hypercalcaemia.

Subsidy status

Sevelamer carbonate 800 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. MAF assistance does not apply to lanthanum carbonate 500 mg, 750 mg, and 1000 mg tablets.

Lanthanum and sevelamer for hyperphosphataemia in CKD (1 Oct 2018) [PDF, 461 KB]